Subscribe to our monthly newsletter.
Your email address will never be disclosed to any third party.
Read our privacy notice.


News in brief
11-04-2018  |  259x
Share this item

Symcel partners with Karolinska Institutet

Partnership is to validate calScreener™ in clinical antimicrobial susceptibility testing

11 April 2018: Symcel – the company behind the revolutionary cell-based assay tool for real-time cell metabolism measurements, calScreener™ – has partnered with the Karolinska Institutet in a Horizon 2020 funded project. The collaboration will see Symcel’s calScreener™ technology evaluated as an improved method to test for combinations of antibiotics against extensively drug resistant bacteria in sepsis patients. Associate Professor Christian Giske, Chief Physician in Bacteriology at the Karolinska University Hospital, Sweden, and Chairman of EUCAST, the body which sets the guidelines for antimicrobial susceptibility testing, takes the helm as the project’s academic lead. Professor Giske is tasked with evaluating whether calScreener™ provides a reliable reference point for clinical microbiologists to determine whether an antibiotic is effective in killing multi-resistant bacteria.

“Early results from our initial tests on Symcel’s technology, carried out in our research laboratories, showed that calScreener™ has great promise for use in clinical laboratories and for addressing key challenges in antimicrobial susceptibility testing. Antimicrobial resistance is increasing rapidly and can cause infections that are extremely difficult to treat – sometimes not even a single antimicrobial has remaining activity against such pathogens. Customized diagnostics solutions with rapid and accurate quantitative measurements are essential, particularly ones that have the capability to test several antimicrobials simultaneously – accurately predicting the effects of combination therapy” commented Professor Giske.

The calScreener™ method is well positioned for combination testing due to its total metabolic response in real-time, very high sensitivity and no limit to the number of antimicrobials that the technology can test at once. Combination therapies have emerged as a major new drug development strategy for combating antimicrobial resistance – treating infections with sets of drugs rather than individual ones. This growing trend has been fuelled by the increasing prevalence of infections caused by multi-drug resistant bacteria and exacerbated by the shortage of novel classes of antibiotics entering the clinic.

The project involves a Symcel led consortium spanning 28 months – also comprising Hospital Universitario Ramón y Cajal, Careggi University Hospital, Erasmus MC, Rigshospitalet and IHE, as well as the Karolinska Institutet, and focused on specific geographies with large resistant problems such as Italy and Spain.

Company information

LABinsights.net LABinsights.de LABinsights.nl
Newsletter archive
Service and contact
ContactDisclaimerPrivacyAdvertisingControl panel log-in